Eli Lilly will harness the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus.

Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.

In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.

Immunosuppressive drugs for inflammatory diseases like rheumatoid arthritis, multiple sclerosis and ulcerative colitis can impair the body’s response to the Covid-19 vaccines from Pfizer/BioNTech and Moderna, according to new data.

Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.

In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.

Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.

Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.

Texas-based Molecular Templates (MTEM) and Bristol Myers Squibb forged a strategic research collaboration worth a potential $1.3 billion to discover and develop multiple oncology therapies using a next-generation engineered toxin body platform.

Switzerland-based AC Immune SA announced positive interim results from the company’s ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.